Revved-up Tecfidera sales power Biogen in Q4

Eric Palmer

CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. But the drugmaker got those winds into its sails, and , this quarter, racing past Wall Street expectations as MS med regained the momentum lost earlier last year.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS